美罗华联合ICE方案治疗复发非霍奇金淋巴瘤疗效观察

目的观察和评价美罗华联合ICE方案治疗复发非霍奇金淋巴瘤(NHL)疗效及不良反应。方法 20例复发性NHL患者采用美罗华联合ICE方案化疗。美罗华375 mg/m2,静脉滴注,第1天;异环磷酰胺1.5 g/m2,静脉滴注,第2~4天;卡铂200 mg/m2,避光静脉滴注,第2~4天;依托泊苷,100 mg/m2,静脉滴注,第2~4天。21~28 d为1个周期,每例患者至少完成2个周期以上治疗后评价临床疗效及不良反应发生情况。结果 20例患者中,完全缓解6例,部分缓解7例,无变化3例,进展4例,临床总有效率为65.0%。主要不良反应为骨髓抑制,主要表现为白细胞减少和血小板减少,其次为恶心呕吐,心脏、肝脏、肾脏、神经毒性和皮肤黏膜炎较少见。随访至2012年8月,中位生存期14个月。结论美罗华联合ICE方案可作为复发性中高度恶性NHL的治疗方案。

Observation of patients with recurrent non-Hodgkin lymphoma treated with rituximab in combination of CHOP regimen

Objective To explore and observe the clinical effect and side effect of patients with recurrent non-Hodgkin lymphoma(NHL) treated by rituximab in combination of CHOP regimen.Methods Twenty patients with recurrent non-Hodgkin lymphoma were treated with rituximab in combination of CHOP regimen(Rituximab 375 mg/m2,intravenous drip,d1;isosfamide 1.5 g/m2,intravenous drip,d2-4,21-28 d in one cycle).The clinical effect and side effect of patients who received at least 2 cycles were evaluated.Results In 20 cases,CR in 6 cases(30.0%),PR in 7 cases(35.0%),NC in 3 cases(15.0%),and PD in 4 cases(20.0%).The total clinical effectiveness rate was 65.0%(13/20).Major side effect was bone marrow suppression,main expression included neutropenia and thrombocytopenia,and less expression included nausea and vomiting,toxicity in heart,liver,kidney,nerve and mucosa inflammation.Follow-up was conduted until August,2012 with a medium survival time of 14 months.Conclusion Rituximab in combination of CHOP regimen can be used as clinical therapy of recurrent non-Hodgkin lymphoma.